Literature DB >> 11489136

The ubiquitin protein catabolic disorders.

R Layfield1, A Alban, R J Mayer, J Lowe.   

Abstract

The ubiquitin-proteasome system of intracellular proteolysis is essential for cell viability. We propose the concept that neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as other conditions including some types of cancer, collectively represent a raft of 'ubiquitin protein catabolic disorders' in which altered function of the ubiquitin-proteasome system can cause or directly contribute to disease pathogenesis. Genetic abnormalities within the ubiquitin pathway, either in ubiquitin-ligase (E3) enzymes or in deubiquitinating enzymes, cause disease because of problems associated with substrate recognition or supply of free ubiquitin, respectively. In some cases, mutations in protein substrates of the ubiquitin-proteasome system may directly contribute to disease progression because of inefficient substrate recognition. Mutations in transcripts for the ubiquitin protein itself (as a result of 'molecular misreading') also affect ubiquitin-dependent proteolysis with catastrophic consequences. This has been shown in Alzheimer's disease and could apply to other age-associated neurodegenerative conditions. Within the nervous system, accumulation of unwanted proteins as a result of defective ubiquitin-dependent proteolysis may contribute to aggregation events, which underlie the pathogenesis of several major human neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11489136     DOI: 10.1046/j.1365-2990.2001.00335.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  14 in total

Review 1.  Neuroimmunopathology in a murine model of neuropsychiatric lupus.

Authors:  David A Ballok
Journal:  Brain Res Rev       Date:  2006-12-20

Review 2.  Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution.

Authors:  Massimo Stefani; Christopher M Dobson
Journal:  J Mol Med (Berl)       Date:  2003-08-27       Impact factor: 4.599

3.  Studying protein phosphorylation in low MW CSF fractions with capLC-ICPMS and nanoLC-CHIP-ITMS for identification of phosphoproteins.

Authors:  Jenny Ellis; Rudolf Grimm; Joseph F Clark; Gail Pyne-Gaithman; Steve Wilbur; Joseph A Caruso
Journal:  J Proteome Res       Date:  2008-09-23       Impact factor: 4.466

4.  The mouse mahoganoid coat color mutation disrupts a novel C3HC4 RING domain protein.

Authors:  Loan K Phan; Feng Lin; Charles A LeDuc; Wendy K Chung; Rudolph L Leibel
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

Review 5.  The cell biology of alpha-synuclein: a sticky problem?

Authors:  Nelson B Cole; Diane D Murphy
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 6.  Linkage between the proteasome pathway and neurodegenerative diseases and aging.

Authors:  Sophie Vigouroux; Marièle Briand; Yves Briand
Journal:  Mol Neurobiol       Date:  2004-10       Impact factor: 5.590

7.  Mitochondrial dysfunction precedes neurodegeneration in mahogunin (Mgrn1) mutant mice.

Authors:  Kaihua Sun; Brian S Johnson; Teresa M Gunn
Journal:  Neurobiol Aging       Date:  2007-08-27       Impact factor: 4.673

8.  Cardiovascular disease could be contained based on currently available data!

Authors:  Okom Nkili F C Ofodile
Journal:  Dose Response       Date:  2006-09-23       Impact factor: 2.658

9.  AlzPathway: a comprehensive map of signaling pathways of Alzheimer's disease.

Authors:  Satoshi Mizuno; Risa Iijima; Soichi Ogishima; Masataka Kikuchi; Yukiko Matsuoka; Samik Ghosh; Tadashi Miyamoto; Akinori Miyashita; Ryozo Kuwano; Hiroshi Tanaka
Journal:  BMC Syst Biol       Date:  2012-05-30

10.  Embryonic demise caused by targeted disruption of a cysteine protease Dub-2.

Authors:  Kwang-Hyun Baek; Heyjin Lee; Sunmee Yang; Soo-Bin Lim; Wonwoo Lee; Jeoung Eun Lee; Jung-Jin Lim; Kisun Jun; Dong-Ryul Lee; Young Chung
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.